cell therapy in cardiovascular diseases
DESCRIPTION
stem cell therapy and cell therapy is a new emerging way in medicine and in cardiovascular diseases.TRANSCRIPT
![Page 1: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/1.jpg)
![Page 2: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/2.jpg)
Cell Therapy For Cardiovascular Diseases
![Page 3: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/3.jpg)
Supervisors:Prof. Dr.
Ahmed Mohamed Zaghlol Darwish Professor of Cardiology
Faculty of Medicine Tanta University
Prof. Dr.
Magdy Mohamed El-MasryProfessor of Cardiology
Faculty of Medicine Tanta University
Prof. Dr.
Samia Mahmoud Sharf El-deenProfessor of Cardiology
Faculty of Medicine Tanta University
![Page 4: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/4.jpg)
Definitions
![Page 5: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/5.jpg)
Definition: Stem cells:• Cells with 3 major criteria:
Self renewal.Capacity of clonal expansion.Multipotant differentiation.
.
![Page 6: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/6.jpg)
Definition: Progenitor cells:
Can differentiate into a specific type of cells. But, they are more specific than stem cells:
they are pushed to differentiate into their "target" cells.
![Page 7: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/7.jpg)
Classification of cells according to their potency
![Page 8: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/8.jpg)
Classification of cells according to their potency:
• Totipotent stem cells: Produce all types of tissue including placenta.Eg. Early embryonic cells.
• Pleuripotent stem cells :Produce all types of tissue except placenta.EG. (ESCs).
![Page 9: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/9.jpg)
Classification of cells according to their potency:
• Multipotent stem cells:Produce cells of a closely related family .Eg. (HSCs) that differentiate to red blood
cells, white blood cells and platelets.
• Unipotent stem cells :Produce only one type of cells and have the
ability of self renewal.Eg. epidermal stem cells.
![Page 10: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/10.jpg)
Classification of cells according to their source.
![Page 11: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/11.jpg)
Classification of cells according to their source:
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 12: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/12.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 13: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/13.jpg)
Embryonic Stem Cells. Are isolated from the inner cell mass of the
blastocyst.
![Page 14: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/14.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 15: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/15.jpg)
Bone Marrow–Derived Stem/ Progenitor Cells
![Page 16: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/16.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 17: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/17.jpg)
Hematopoietic stem cells• Sources :
i. Umbilical cord blood (1 per 1 million nucleated cell).
ii. Adult bone marrow (1 per 3 million nucleated cell).
iii. Mobilized peripheral blood (1 per 6 million nucleated cell).
Capable of unlimited cell proliferation in bone marrow producing mature blood cells.
![Page 18: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/18.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 19: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/19.jpg)
Mesenchymal (stromal) stem cells:• Present as a rare population of cells in bone
marrow (0.001% to 0.01% of the nucleated cells).
• Other sources of MSC including placenta, adipose tissue, cord blood and liver.
• They can be cloned and expanded in vitro more than 1 million-fold and retain the ability to differentiate to several cells of mesodermal origin.
![Page 20: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/20.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs).
Endothelial progenitor cells. Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 21: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/21.jpg)
Endothelial progenitor cells.• Cells can give rise to endothelial cells and
contribute to endothelial recovery and new capillary formation after ischemia.
• Sources of endothelial progenitor cells:i. Bone marrow-derived EPCs.ii. Non Bone marrow-derived EPCs: Which arise from Various tissues, including adipose tissue,
neuronal tissue, and the heart itself.
![Page 22: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/22.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 23: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/23.jpg)
Umbilical Cord Blood Cells.• Perfect source for cell-based therapy as they
are rich in both stem and progenitor cells.
• No ethical limitations regarding its use.
• No risks to the mother or to the newborn in collecting the cells after labor.
• There are many public and private UCB banks worldwide with cells readily available for transplantation at the most optimal time.
![Page 24: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/24.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells.
Resident cardiac stem/progenitor cells. Adipose-derived stem cells. Skeletal myoblasts.
![Page 25: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/25.jpg)
Resident cardiac stem/progenitor cells.
• Recently it was proven that adult heart is an organ with regeneration capacity.
• This regeneration capacity are likely due to presence of defined pool of resident progenitor cells.
• These cells are responsible for the normal turnover of cardiomyocytes during physiologic growth and aging.
![Page 26: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/26.jpg)
Resident cardiac stem/ progenitor cells have 4 populations according to their cell marker:
1. Cardiac side population (SP) cells.2. c-kit positive cardiac stem cells.3. Sca-1 positive cardiac progenitor cells.4. Cardiosphere-derived cardiac stem
cells
Resident cardiac stem/progenitor cells.
![Page 27: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/27.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells.
Adipose-derived stem cells. Skeletal myoblasts.
![Page 28: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/28.jpg)
Adipose-derived stem cells.
• Recent studies have suggested that stem cells are present within the adipose tissue.
• This Adipose-derived stem cells, like MSCs, have the ability to differentiate toward the osteogenic, adipogenic, myogenic, chondrogenic and neurogenic cells.
• The ease of access to fat and its abundance makes adipose tissue a potentially useful source of stem cells for clinical applications.
![Page 29: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/29.jpg)
Embryonic Stem Cells. Bone Marrow–Derived Stem/Progenitor Cells:
Hematopoietic stem cells (HSCs). Mesenchymal (stromal) stem cells (MSCs). Endothelial progenitor cells.
Umbilical Cord Blood Cells. Resident cardiac stem/progenitor cells. Adipose-derived stem cells.
Skeletal myoblasts.
![Page 30: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/30.jpg)
Skeletal myoblasts.• Skeletal myoblasts were the first candidates for
cardiac repair.
• They are derived from skeletal muscles “satellite cells”.
• They are responsible for regeneration of damaged skeletal muscle after injury.
![Page 31: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/31.jpg)
Methods Of Cell Delivery
![Page 32: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/32.jpg)
• The ideal modality of cell delivery should have the following characteristics:
Safe with minimal complications.Easily performed.Cost benefit ratio within range.Applicable across a wide range of clinical
scenariosTargeting of the cells precisely in an adequate
cardiac environment.
![Page 33: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/33.jpg)
1) Direct myocardial injection: The most accurate type of delivery that can be
achieved by direct visualization during thoracotomy.
Can be done either as an adjunct to CABG or as sole therapy.
![Page 34: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/34.jpg)
• Disadvantages:Possible arrhythmogenicity.Need for concomitant open-heart surgery.Can’t be repeated if needed.
![Page 35: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/35.jpg)
2) Transcatheter endomyocardial injection: Less invasive technique.
Electromechanical testing to confirm the presence of ischemic or dead myocardium should be done before cell delivery.
![Page 36: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/36.jpg)
• Disadvantages:Complex procedure as electromechanical
map of the left ventricular chamber is required.
![Page 37: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/37.jpg)
3) Intracoronary cell injection: Most popular mode of cell delivery especially
after AMI.
It can be performed at the same time of (PCI).
Disadvantages:Not suitable for all cell types as larger cells as MSCs may occlude the Microcirculation.
![Page 38: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/38.jpg)
![Page 39: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/39.jpg)
4) Intravenous injection: The simplest and least invasive delivery route and
produces minimal complications.
Can easily be repeated if necessary.
Disadvantage:low percentage of cells delivered.
![Page 40: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/40.jpg)
5) Intramyocardial injection via coronary vein
The catheter can enter the coronary sinus directed by IVUS.
The needle is directed toward the myocardium through which cells and drugs can be injected.
The safety and feasibility of this new catheter approach needs to be investigated.
![Page 41: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/41.jpg)
Mechanisms of Myocardial Repair
![Page 42: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/42.jpg)
• Cell therapy seems to act through three mechanistic pathways:
i. Differentiation into cardiomyocytes.ii. Cell Fusion with host cardiomyocytes.iii. Paracrine effects.
![Page 43: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/43.jpg)
I. Differentiation into cardiomyocytes
The cell differentiation to cardiomyocytes is influenced by:high level of circulating stem cells.Organ damage Signaling factors as G-CSF, VEGF. cell-to-cell contact with cardiomyocytes.
Doubt still exists if the trasdifferentiated cells can participate in the actively contractile myocardium.
![Page 44: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/44.jpg)
II. Cell Fusion with host cardiomyocytes.
Myocardial regeneration could result from fusion of the transplanted stem cell with existing cardiac cells “hybrid cells”.
Donor cell genes may compensate for the lost genetic material from the host nucleus during ischemic injury.
![Page 45: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/45.jpg)
III. Paracrine effects:
Implanted cells releases a number of local cytokines and growth factors as TNF-α, VEGF, IGF, Cardiotrophin-1.
These factors: I. Inhibit cardiomyocyte apoptosis.II. Enhance angiogenesis.III. Rescue injured myocytes.IV. Inhibit pathologic remodeling.
![Page 46: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/46.jpg)
Cell Therapy for Acute Myocardial Infarction
![Page 47: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/47.jpg)
Most of the clinical trials in the field of AMI used BMCs with Conflicting Results.
MSCs was used in one trail by Chen et al, With significant improvement of LVEF and LVEDd.
Further larger randomized trails is needed in this field.
![Page 48: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/48.jpg)
![Page 49: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/49.jpg)
![Page 50: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/50.jpg)
Cell Therapy in End-stage Ischemic Heart Disease With no Further Revascularization
Options
![Page 51: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/51.jpg)
The main therapeutic goal for these patients is to improve blood supply.
Most trials have been small phase 1 studies and shown improved perfusion and myocardial function.
Concerns were raised by observation that some patient developed an acute coronary syndrome and fatal myocardial infarction.
![Page 52: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/52.jpg)
Cell Therapy For Ischemic Cardiomyopathy & Chronic
Heart Failure
![Page 53: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/53.jpg)
In the field of heart failure results of initial attempts of cell therapy have been more heterogeneous.
Two main cells was involved in HF cell therapy trials:
Skeletal Myoblasts.Bone Marrow Cells.
![Page 54: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/54.jpg)
Skeletal Myoblasts clinical trails:
In most trials, improvements of regional wall motion and global LVEF have been noted after myoblast injections.
However, myoblast injections increase the risk of ventricular arrhythmias in this patient, with unclear mechanisms.
![Page 55: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/55.jpg)
Bone Marrow Cells clinical trails: In most BMCs trials showed improved cardiac
function with less complications compared with SKMB trials.
![Page 56: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/56.jpg)
Cell Therapy For Pulmonary Arterial
Hypertension
![Page 57: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/57.jpg)
One of the more recent applications of cell therapy with very limited clinical experience.
Role of cell therapy in PAH either: Contributing to blood vessel thickening
(remodeling) and blockage in PAH.Repair damaged blood vessels and restore
more normal blood flow in the lung.
![Page 58: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/58.jpg)
Cell Therapy For Peripheral Vascular
disease
![Page 59: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/59.jpg)
Cell therapy can induce new vessels formation by 2 mechanisms:i. Vasculogenic effect: by incorporation into
newly forming vessels.ii. Trophic effect: delivering angiogenic growth
factors.
Overall, clinical trials reported encouraging effect of cell therapy in this field.
![Page 60: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/60.jpg)
Drawbacks to Cell Therapy in
Cardiovascular Diseases
![Page 61: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/61.jpg)
Cellular therapy has both theoretical and reported safety concerns.
These adverse effects include:
![Page 62: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/62.jpg)
1) Atherosclerosis:Neointimal hyperplasia due to excessive
accumulation of SMCs derived from donor cells.
2) Post-stenting Restenosis:Caused by differentiation of progenitor cells
into SMCs within the stented segment
![Page 63: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/63.jpg)
3) G-CSF Induced Acute Coronary Syndromes:Possible due to increased CRP level might
induce plaque destabilization and rupture.
4) Arrhythmogenesis:A common adverse effect with SKMB
trafustion.May be due to the ability of myoblasts to fire
action potentials that may induce deleterious extrasystoles
![Page 64: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/64.jpg)
5) Stem Cell Immunogenicity:Allogenic origin of cells has raised concern of
allograft rejection and the need for immunosuppressive agents.
6) Tumorigenesis:The pluripotency of ESCs may enhance
undefined growth in vivo, giving rise to teratomas.
![Page 65: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/65.jpg)
7) Stem Cell Metastasis:Also transplanted ESCs can form teratomas in
distant sites such as the submandible and femur.
8) Ethical concerns: Regarding ESCs use as they are isolated from
the early embryo “destroying the embryo”
![Page 66: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/66.jpg)
![Page 67: Cell therapy in cardiovascular diseases](https://reader033.vdocument.in/reader033/viewer/2022042700/554b2474b4c905a2058b465e/html5/thumbnails/67.jpg)
Thank you